A carregar...
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate
Dimethyl fumarate (DMF) is the most recent oral disease-modifying therapy approved by the US Food and Drug Administration and is indicated for the treatment of relapsing forms of multiple sclerosis (MS). Prior to approval for use in MS, DMF and its active metabolite, monomethyl fumarate, had been us...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4094574/ https://ncbi.nlm.nih.gov/pubmed/25045248 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S50962 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|